Therefore, it is conceivable that immune complexes formed between CitPG and anti-CitPG Abs are able to trigger local inflammatory reactions, thus contributing to the initiation or perpetuation of joint inflammation in ACPA+ RA patients. The gene discussed is PRTN3; the disease is rheumatoid arthritis.